Home » Clinical Trials » Leukemia » NCT05467254
NCT05467254

To Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Study Summary

This is an open label, phase I study to assess the safety and efficacy of CLL1+CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia

Interested in this trial?

Submit an Inquiry

Interventions

CLL1+CD33 CAR-TBIOLOGICAL
CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.

Study Locations

FacilityCityStateCountry
Mingming Zhang ZhangHangzhouChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026